Possibilities of optimizing therapy in COVID-19 survivors with focal epilepsy

• Published in: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova Vol. 123; no. 3; p. 130
• Main Authors: Ponomareva, I V, Stepanova, S B, Reneva, S A, Sorokova, E V, Vagina, M A, Makodzeba, O A, Galiullin, T R
• Format: Journal Article
• Language: English; Russian
• Published: Russia (Federation) 2023
• Subjects: Adult; Anticonvulsants - therapeutic use; Asthenia - drug therapy; COVID-19; Epilepsies, Partial - drug therapy; Epilepsy - drug therapy; Epilepsy, Tonic-Clonic; Humans; Quality of Life; SARS-CoV-2; Seizures - drug therapy; COVID-19; epilepsy; antiepileptic drugs; fatigue; phenosanic acid; tolerability; frequency of bilateral tonic-clonic seizures; quality of life; efficacy
• ISSN: 1997-7298
• DOI: 10.17116/jnevro2023123031130

To study the effect of phenosanoic acid therapy on the frequency of seizures, asthenia and quality of life of adult patients with focal epilepsy who had a new coronavirus infection caused by SARS-CoV-2.
The data of 20 patients with focal epilepsy who suffered COVID-19 and received therapy with phenosanic acid (Dibufelon) were studied. The frequency of epileptic seizures, the severity of asthenia and the quality of life were evaluated according to clinical scales.
Significant decrease in the frequency of bilateral tonic-clonic seizures and focal seizures with loss of consciousness was recorded. There was a significant improvement in the quality of life. There was no significant dynamics of asthenia against the background of taking the drug phenosanic acid in patients.
The preparation of phenosanic acid can be an effective means of add-on therapy in patients with epilepsy who have undergone COVID-19.